Our results of phenotypic changes in cancer cells or mouse hearts following exposure to both drugs or genetic interventions support the notion that Hippo pathway activation/YAP inhibition constitutes the underlying mechanism leading to mitochondrial damage and ultimately anti-cancer efficacy or cardiomyopathy. Here, YAP1 is linked to cardiomyopathy.